NMR

NMR Stock -- What's In It For Investors?

We've been asking ourselves recently if the market has placed a fair valuation on Nomura. Let's dive into some of the fundamental values of this large-cap Finance company to determine if there might be an opportunity here for value-minded investors.

Nomura's P/B and P/E Ratios Are Higher Than Average:

Nomura Holdings, Inc. provides various financial services to individuals, corporations, financial institutions, governments, and governmental agencies worldwide. The company belongs to the Finance sector, which has an average price to earnings (P/E) ratio of 14.34. In contrast, Nomura has a trailing 12 month P/E ratio of 18.2 based on its earnings per share of $0.22.

Nomura has moved 9.1% over the last year compared to 20.4% for the S&P 500 -- a difference of -11.0%. Nomura has a 52 week high of $4.23 and a 52 week low of $3.0.

The Company Has a Highly Leveraged Balance Sheet and a Declining EPS Growth Trend:

2020-03-31 2021-03-31 2022-03-31 2023-03-31
Revenue (MM) $1,072,799 $1,243,866 $1,143,717 $1,150,541
Interest Income (MM) $129,819 $141,103 $54,113 -$36,459
Net Margins 20.23% 12.31% 12.5% 8.06%
Net Income (MM) $216,998 $153,116 $142,996 $92,786
Depreciation & Amort. (MM) -$63,583 -$63,846 -$59,524 -$61,424
Earnings Per Share $66.2 $48.63 $45.23 $0.22
EPS Growth n/a -26.54% -6.99% -99.51%
Diluted Shares (MM) 3,277 3,147 3,159 3,005
Free Cash Flow (MM) -$222,688 $545,895 -$1,480,041 -$1,145,915
Capital Expenditures (MM) -$206,745 -$119,875 -$111,331 -$171,165
Long Term Debt (MM) $8,493,376 $8,367,527 $9,654,597 $10,733,529
Net Debt / EBITDA 13.9 13.01 19.72 29.06

Nomura has declining EPS growth, negative and highly variable cash flows, and a highly leveraged balance sheet. Nomura has stable revenues and decreasing reinvestment in the business and average net margins with a negative growth trend.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS